查詢結果分析
相關文獻
- Cost-Effectiveness Analysis of Tissue Plasminogen Activator for Acute Ischemic Stroke: A Comparative Review
- 急性缺血性腦中風之早期治療
- 2023臺灣腦中風學會急性缺血中風動脈內血栓移除治療指引更新
- 提升缺血性腦中風病人緊急照護品質
- 以動脈注射血栓溶劑治療急性缺血性腦中風:七例報告
- 成功使用血栓溶解劑治療急性缺血性腦中風:一病例報告暨文獻回顧
- Cranial Computed Tomography in Ischemic Stroke Patients with and without Dementia--A Prospective Study
- 缺血性腦中風的治療
- Common Carotid Artery Thrombosis Causing Ischemic Stroke in a Patient with Systemic Lupus Erythematosus
- 使用血栓溶解劑治療急性缺血性腦中風--病例報告
頁籤選單縮合
題名 | Cost-Effectiveness Analysis of Tissue Plasminogen Activator for Acute Ischemic Stroke: A Comparative Review=應用靜脈血栓溶解劑治療急性缺血性腦中風的成效分析:比較性回顧 |
---|---|
作者 | 曾美君; 張谷州; | 書刊名 | Acta Neurologica Taiwanica |
卷期 | 13:3 2004.09[民93.09] |
頁次 | 頁149-155 |
分類號 | 415.922 |
關鍵詞 | 靜脈血栓溶解劑; 缺血性腦中風; 腦中風; Review; Cerebral infarction; Tissue plasminogen activator; Costs and cost analysis; |
語文 | 英文(English) |
英文摘要 | Purpose: This work was undertaken to review current evidence of cost-effectiveness analysis (CEA) on thrombolysis for acute ischemic stroke. Methods: An electronic search via PubMed, from 1995 until May 2004, was performed. The methodsundertaken by these studies were examined with particular attention to their modeling assumptions, sources of data, and outcome measures. Results: Three comprehensive CEAs of rtPA (recombinant tissue plasminogen activator) for acute ischemic troke were reviewed. These studies were from the United States, Canada, and the United Kingdom. All hese studies employed the perspective of a healthcare system and used a Markov decision-analytic modelling approach. Estimates of effectiveness of rtPA were based on the National Institute of Neurological isorders and Stroke (NINDS) rtPA Stroke Trial, literature-derived values or a stroke registry. In each tudy, functional outcome measured by the modified Rankin Scale was used to represent health states, nd quality-adjusted life year gained was the health outcome summary measure. The cost-effectiveness of rtPA therapy varied in magnitude, but seemingly with same positive implications. Conclusions: Cost-effectiveness analysis requires information on an intervention’s effectiveness and country- specific sources of epidemiological and resource utilization data, most of which are not yet available n Taiwan. Despite the limitations, CEA is essential if a healthcare system would like to contain costs while maintaining, or improving, quality of care. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。